Ind-Swift Laboratories Limited (INDSWFTLAB) - Total Assets
Based on the latest financial reports, Ind-Swift Laboratories Limited (INDSWFTLAB) holds total assets worth Rs15.44 Billion INR (≈ $167.02 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Ind-Swift Laboratories Limited debt service capacity to assess how comfortably operating cash covers total debt obligations.
Ind-Swift Laboratories Limited - Total Assets Trend (2006–2025)
This chart illustrates how Ind-Swift Laboratories Limited's total assets have evolved over time, based on quarterly financial data. See INDSWFTLAB book value for net asset value and shareholders' equity analysis.
Ind-Swift Laboratories Limited - Asset Composition Analysis
Current Asset Composition (March 2025)
Ind-Swift Laboratories Limited's total assets of Rs15.44 Billion consist of 60.2% current assets and 39.8% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 29.8% |
| Accounts Receivable | Rs1.65 Billion | 11.4% |
| Inventory | Rs1.14 Billion | 7.9% |
| Property, Plant & Equipment | Rs2.60 Billion | 18.1% |
| Intangible Assets | Rs106.81 Million | 0.7% |
| Goodwill | Rs0.00 | 0.0% |
Asset Composition Trend (2006–2025)
This chart illustrates how Ind-Swift Laboratories Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Ind-Swift Laboratories Limited.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Ind-Swift Laboratories Limited's current assets represent 60.2% of total assets in 2025, an increase from 39.4% in 2006.
- Cash Position: Cash and equivalents constituted 29.8% of total assets in 2025, up from 0.8% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 1.0% in 2006.
- Asset Diversification: The largest asset category is property, plant & equipment at 18.1% of total assets.
Ind-Swift Laboratories Limited Competitors by Total Assets
Key competitors of Ind-Swift Laboratories Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Beijing Sun Novo Pharmaceutical Research Co Ltd
SHG:688621
|
China | CN¥2.30 Billion |
|
Guizhou Xinbang Pharmaceutical Co Ltd
SHE:002390
|
China | CN¥8.59 Billion |
|
Guangdong Lifestrong Pharmacy Co. Ltd.
SHE:301111
|
China | CN¥925.41 Million |
|
Jw Pharmac
KO:001060
|
Korea | ₩605.27 Billion |
|
Kamada
TA:KMDA
|
Israel | ILA377.21 Million |
|
Samjin Pharm
KO:005500
|
Korea | ₩449.14 Billion |
Ind-Swift Laboratories Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.03 | 3.57 | 2.85 |
| Quick Ratio | 3.51 | 3.51 | 1.78 |
| Cash Ratio | 1.91 | 2.67 | 0.00 |
| Working Capital | Rs6.34 Billion | Rs4.22 Billion | Rs5.89 Billion |
Ind-Swift Laboratories Limited - Advanced Valuation Insights
This section examines the relationship between Ind-Swift Laboratories Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.92 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | -1.5% |
| Total Assets | Rs14.38 Billion |
| Market Capitalization | $214.71 Million USD |
Valuation Analysis
Below Book Valuation: The market values Ind-Swift Laboratories Limited's assets below their book value (0.01x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Ind-Swift Laboratories Limited's assets decreased by 1.5% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Ind-Swift Laboratories Limited (2006–2025)
The table below shows the annual total assets of Ind-Swift Laboratories Limited from 2006 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | Rs14.38 Billion ≈ $155.55 Million |
-1.51% |
| 2024-03-31 | Rs14.60 Billion ≈ $157.94 Million |
-19.94% |
| 2023-03-31 | Rs18.24 Billion ≈ $197.27 Million |
+1.29% |
| 2022-03-31 | Rs18.01 Billion ≈ $194.75 Million |
-0.97% |
| 2021-03-31 | Rs18.18 Billion ≈ $196.66 Million |
-2.76% |
| 2020-03-31 | Rs18.70 Billion ≈ $202.23 Million |
-2.80% |
| 2019-03-31 | Rs19.24 Billion ≈ $208.07 Million |
-4.89% |
| 2018-03-31 | Rs20.23 Billion ≈ $218.78 Million |
-5.36% |
| 2017-03-31 | Rs21.38 Billion ≈ $231.16 Million |
-3.68% |
| 2016-03-31 | Rs22.19 Billion ≈ $240.00 Million |
-1.10% |
| 2015-03-31 | Rs22.44 Billion ≈ $242.66 Million |
-3.27% |
| 2014-03-31 | Rs23.20 Billion ≈ $250.86 Million |
-2.29% |
| 2013-03-31 | Rs23.74 Billion ≈ $256.75 Million |
+7.66% |
| 2012-03-31 | Rs22.05 Billion ≈ $238.49 Million |
+26.84% |
| 2011-03-31 | Rs17.39 Billion ≈ $188.03 Million |
+36.44% |
| 2010-03-31 | Rs12.74 Billion ≈ $137.81 Million |
+32.73% |
| 2009-03-31 | Rs9.60 Billion ≈ $103.83 Million |
+19.16% |
| 2008-03-31 | Rs8.06 Billion ≈ $87.14 Million |
+15.48% |
| 2007-03-31 | Rs6.98 Billion ≈ $75.46 Million |
+35.71% |
| 2006-03-31 | Rs5.14 Billion ≈ $55.60 Million |
-- |
About Ind-Swift Laboratories Limited
Ind-Swift Laboratories Limited, together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients (APIs), intermediates, and formulations in India and internationally. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, Parkinson's disease, hy… Read more